Top Story

HD IL-2 extends OS in malignant melanoma

April 18, 2015

NEW YORK — Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

Prior studies designed to assess the efficacy of high-dose interleukin-2 [IL-2 (Proleukin, Prometheus)] in patients with metastatic melanoma showed an overall response rate of 16% and a median OS of 11.4 months. However, the studies that supported the agent’s regulatory approval were conducted more than 15 years ago, prior to the development of targeted therapies and checkpoint inhibition, according to study background.

Oncology Nursing Society to kick off its 40th Annual Congress

April 17, 2015
The Oncology Nursing Society will kick off its 2015 Annual Congress on Wednesday, April 22 in Orlando, Fla., marking its 40th year of providing comprehensive nursing…
FDA News

FDA grants orphan drug designation to Samcyprone for malignant stage IIb to IV melanoma

April 17, 2015
RXi Pharmaceuticals announced it has received orphan drug designation from the FDA for Samcyprone, its clinical candidate for treating malignant melanoma stage IIb to…
FDA News

FDA grants orphan drug designation to Reolysin for malignant gliomas

April 17, 2015
The FDA today granted orphan drug designation to pelareorep for the treatment of patients with malignant gliomas, according to a press release from the drug’s…
Sunit Das, MD, PhD In the Journals

Hypofractionated radiation, temozolomide effective in elderly patients with glioblastoma

April 17, 2015
Hypofractionated radiotherapy or temozolomide monotherapy may be a viable treatment option for elderly patients with glioblastoma multiforme, according to results of a…
More News Headlines »
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »